Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Junichi Matsubara1,6, Kazufumi Honda1, Masaya Ono1, Shigeki Sekine2, Yoshinori Tanaka2, Michimoto Kobayashi2, Giman Jung2, Tomohiro Sakuma2, Shoji Nakamori3, Naohiro Sata4, Hideo Nagai4, Tatsuya Ioka4, Takuji Okusaka4, Tomoo Kosuge4, Akihiko Tsuchida5, Masashi Shimahara5, Yohichi Yasunami6, Tsutomu Chiba6, and Tesshi Yamada1

Abstract

Background: The aim of this study was to identify a new plasma biomarker for use in early detection of colorectal cancer.

Methods: Using the combination of hollow fiber membrane (HFM)-based low-molecular weight protein enrichment and two-dimensional image converted analysis of liquid chromatography and mass spectrometry (2DICAL), we compared the plasma proteome of 22 colorectal cancer patients with those of 21 healthy controls. An identified biomarker candidate was then validated in two larger cohorts [validation-1 (n = 210) and validation-2 (n = 113)] using a high-density reverse-phase protein microarray.

Results: From a total of 53,009 mass peaks, we identified 103 with an area under curve (AUC) value of 0.80 or higher that could distinguish cancer patients from healthy controls. A peak that increased in colorectal cancer patients, with an AUC of 0.81 and P value of 0.0004 (Mann–Whitney U test), was identified as a product of the PLIN2 gene [also known as perilipin-2, adipose differentiation-related protein (ADRP), or adipophilin]. An increase in plasma adipophilin was consistently observed in colorectal cancer patients, including those with stage I or stage II disease (P < 0.0001, Welch’s t test). Immunohistochemical analysis revealed that adipophilin is expressed primarily in the basal sides of colorectal cancer cells forming polarized tubular structures, and that it is absent from adjacent normal intestinal mucosae.

Conclusions: Adipophilin is a plasma biomarker potentially useful for the detection of early-stage colorectal cancer.

Impact: The combination of HFM and 2DICAL enables the comprehensive analysis of plasma proteins and is ideal for use in all biomarker discovery studies. Cancer Epidemiol Biomarkers Prev; ©2011 AACR.

Introduction

Colorectal cancer is the second leading cause of cancer deaths in Western countries (1) and is the third leading cause of cancer deaths in Japan, where there were more than 43,000 estimated colorectal cancer deaths in 2008 (2). Treatment of colorectal cancer without metastasis is relatively uncomplicated, and a favorable prognosis can be expected for these patients (3, 4). However, the 5-year survival rate of patients with metastatic colorectal cancer is estimated to be less than 5% (5), underscoring the importance of early detection. The modality used most commonly for colorectal cancer mass screening is fecal occult blood (FOB) test. Three large randomized trials showed that inclusion of FOB in colorectal cancer screening significantly reduces the rates of colorectal cancer mortality (6–8). However, FOB has a relatively high false positive rate (9, 10), and as a result, a large number of healthy individuals receive radiological or endoscopic
of differential expression of colorectal cancer cells in the plasma proteome of colorectal cancer patients. We report the identification of adipophilin, a novel tumor marker for the early diagnosis of colorectal cancer. The LMW plasma protein fraction is made up of various functional proteins with high efficiency and reproducibility (22). Here, we report the identification of adipophilin, an adipose differentiation-related protein, as a novel tumor marker for colorectal cancer through a comprehensive analysis of the LWM plasma proteome of colorectal cancer patients using HFMT and 2DICAL technologies.

Patients and Methods

Plasma samples

Plasma samples were collected prospectively from 366 individuals and then split randomly into 3 cohorts (training, validation-1 (V1), and validation-2 (V2); Table 1). The cohorts were essentially hospital based and consisted of healthy volunteers and newcomers (primarily to gastrointestinal services) between August 2006 and October 2008 at the following 7 hospitals in Japan: National Cancer Center Hospital (NCCH; Tokyo), Osaka National Hospital (ONH; Osaka), Jichi Medical School Hospital (JMS; Shimotsuke), Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka), Tokyo Medical University Hospital (TMUH; Tokyo), Osaka Medical College Hospital (OMC; Osaka), and Fukuoka University Hospital (Fukuoka). This multi-institutional collaborative study group was organized by the "Third Term Comprehensive Control Research for Cancer" conducted by the Ministry of Health, Labour and Welfare of Japan and joined the International Cancer Biomarker Consortium (23). Written informed consent was obtained from every subject.

All patients diagnosed as having cancer had histologic or cytologic proof of colorectal adenocarcinoma. Demographic and laboratory data for the cases are summarized in Table 1. The staging of cancer was defined according to TNM classification by the International Union against Cancer (UICC). The Training cohort comprised 43 cases, including untreated colorectal cancer patients from TMUH (n = 8), JMS (n = 9), and ONH (n = 5), and healthy controls from NCCH (n = 2), TMUH (n = 9), OMC (n = 6), and ONH (n = 4). The V1 and V2 cohorts comprised 210 and 113 cases, respectively, from the 7 hospitals as described above. The V1 cohort included 26 patients with colorectal cancer and 109 healthy controls. The V2 cohort comprised 26 patients with colorectal cancer and 87 healthy controls.

For all the samples used in this study, the same protocol was used for blood collection, storage, and freeze/thawing to ensure absence of any preanalytical bias caused by differences in sample handling. Blood was collected in a tube with EDTA at the time of diagnosis. Plasma was separated by centrifugation and frozen at −80°C until analysis. Macroscopically hemolyzed samples were excluded from the present analysis. The protocol of this study was reviewed and approved by the institutional ethics committee board of each participating institute.

Depletion of high-molecular weight plasma proteins

The plasma samples of the training cohort were filtered through a 0.22-μm pore size filter. Five hundred microliter of the sample was diluted by adding 3.5 mL 25 mmol/L ammonium bicarbonate buffer (pH 8.0). The total of 4 mL of the plasma dilution was injected into a HFMT machine (22). After 1 hour of fully automated operation, the solution containing LMW proteins was recovered and lyophilized.

Liquid chromatography mass spectrometry

The HFMT-treated samples were digested with sequencing grade modified trypsin (Promega) and analyzed in duplicate using a nano flow high-performance
liquid chromatography (NanoFrontier nLC; Hitachi High-technologies) connected to an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) mass spectrometer (Q-Tof Ultima; Waters).

Mass spectrometry (MS) peaks were detected, normalized, and quantified using the in-house 2DICAL software package, as described previously (13). A serial identification (ID) number was applied to each of the MS peaks detected (1 to 53,009). The stability of liquid chromatography mass spectrometry (LC-MS) was monitored by calculating the correlation coefficient (CC) and coefficient of variance (CV) of every measurement. For all 53,009 peaks observed in the 43 duplicate runs, the mean CC (± SD) was as high as 0.951 (± 0.039) and the mean CV was as low as 0.054 (± 0.011).

Protein identification by tandem mass spectrometry

Peak lists were generated using the Mass Navigator software package (version 1.2; Mitsui Knowledge Industry) and the peak lists were searched against the SwissProt database (downloaded on April 22, 2009) using the Mascot software package (version 2.2.1; Matrix Science). The search parameters used were as follows: the human protein database was selected; up to 1 missed cleavage was allowed; “none” was designated as the enzyme; mass tolerances for precursor and fragment ions were ± 0.6 and

### Table 1. Clinicopathologic characteristics of cases in the training (n = 43) and validation cohorts (V1: n = 210; V2: n = 113)

<table>
<thead>
<tr>
<th></th>
<th>Training cohort (n = 43)</th>
<th>Validation-1 cohort (n = 210)</th>
<th>Validation-2 cohort (n = 113)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>22</td>
<td>101</td>
<td>26</td>
</tr>
<tr>
<td>Sex, no. of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>14</td>
<td>63</td>
<td>13</td>
</tr>
<tr>
<td>Female</td>
<td>8</td>
<td>38</td>
<td>13</td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>62 (12)</td>
<td>64 (11)</td>
<td>63 (12)</td>
</tr>
<tr>
<td>Tumor location</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Colon</td>
<td>22</td>
<td>88</td>
<td>24</td>
</tr>
<tr>
<td>Rectum</td>
<td>0</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>3</td>
<td>19</td>
<td>12</td>
</tr>
<tr>
<td>II</td>
<td>6</td>
<td>31</td>
<td>5</td>
</tr>
<tr>
<td>III</td>
<td>8</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>IV</td>
<td>5</td>
<td>17</td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>CA19-9</td>
<td>14.7</td>
<td>5.5</td>
<td>9.4</td>
</tr>
<tr>
<td>&gt;37.0 (ULN), no. of patients</td>
<td>6</td>
<td>2</td>
<td>39</td>
</tr>
<tr>
<td>CEA</td>
<td>3.5</td>
<td>1.7</td>
<td>2.6</td>
</tr>
<tr>
<td>&gt;5.0 (ULN), no. of patients</td>
<td>9</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>&gt;1.2 (ULN), no. of patients</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Adipophilin mass spectrometry peak intensity, mean (SD)</td>
<td>320 (375)</td>
<td>96 (78)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Protein intensity, mean (SD)</td>
<td>D</td>
<td>D</td>
<td>3.91 (0.06)</td>
</tr>
</tbody>
</table>

NOTE: Wilcoxon test was applied to assess differences between values.

*Calculated by Fisher’s exact test.

*Calculated using Mann–Whitney U test.

*Calculated using reverse-phase protein microarray (logarithmic variable).

*Calculated using Welch’s t-test.

Abbreviations: NA, not applicable; ULN, upper limit of normal.
± 0.2 Da, respectively; the score threshold was set to \( P < 0.05 \) on the basis of size of the database used in the search. If a peptide matched multiple proteins, the protein name with the highest Mascot score was selected.

**Immunoblot analysis**

Primary antibodies used were mouse monoclonal antibody (mAb) against adipophilin (LifeSpan Biosciences) and mouse mAb against human complement C3b-α (Progen). Ten microliter of 1:50 diluted plasma sample and 0.3 mg of fully recombinant adipophilin (BioVendor) as positive control were separated by SDS-PAGE and electroblotted onto a polyvinylidene difluoride membrane. The membrane was then incubated with primary antibody followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG as described previously (24, 25). Blots were developed using an enhanced chemiluminescence detection system (GE Healthcare).

**Reverse-phase protein microarray**

The plasma samples from the V1 and V2 cohorts were serially diluted 1:32, 1:64, 1:128, and 1:256 using a Biomek 2000 Laboratory Automation Robot (Beckman Coulter), and randomly plotted onto ProtoChip glass slides (Proteogen) in quadruplicate in a 6144-spot/slide format using a Protein Microarrayer Robot (Kaken Geneges). The spotted slides were incubated overnight with the same primary antibody as used in Western blotting. The slides were incubated with biotinylated anti-mouse IgG (Vector Laboratories) followed by streptavidin–HRP conjugate (GE Healthcare). Peroxidase activity was detected using the Tyramide Signal Amplification Cyanine 5 System (PerkinElmer). The slides were counterstained with Alexa Fluor 546–labeled goat anti-human IgG (Invitrogen; spotting control).

The stained slides were scanned on a microarray scanner (InnoScan 700AL; Innopsys). Fluorescence intensity, determined as mean values of quadruplicate samples, was determined using the Mapix software (Innopsys). All intensity values were transformed into logarithmic variables. The reproducibility of our reverse-phase protein microarray assay was reported previously (18).

**Immunohistochemistry**

Twenty colorectal cancer cases were selected from the surgical pathology archive panel of the National Cancer Center Hospital, as described previously (24). Sections (4-μm thick) were cut from paraffin blocks of colorectal cancer tissues and mounted on silanized glass slides and were subsequently stained by the avidin–biotin complex method. The primary antibody was the same as used in immunoblot analysis.

**Statistical analysis**

The statistical significance of intergroup differences was assessed with the Wilcoxon test, Mann-Whitney \( U \) test, Welch’s \( t \) test, Kruskal–Wallis \( U \) test, or Fisher’s exact test, as appropriate. The area under the curve (AUC) value of the receiver operating characteristics (ROC) analysis was calculated for each marker to evaluate its diagnostic significance using ROCKIT software (version 0.9.1; the Kurt Rossmann Laboratories). A composite index of 2 markers was generated using the result of multivariate logistic regression analysis, which also enabled the calculation of sensitivity, specificity, and ROC curves. Statistical analyses were done using an open-source statistical language R (version 2.7.0) with the optional module Design package.

**Results**

**Plasma biomarker discovery by quantitative MS**

To identify a diagnostic biomarker for patients with colorectal cancer including those with early-stage diseases, we compared the plasma proteomes of 22 colorectal cancer patients with those of 21 healthy controls (training cohort) using 2DICAL (Table 1). Among a total of 53,009 independent MS peaks detected within the range 250 to 1,600 m/z and within the time range 20 to 70 minutes, we found 103 peaks with a discriminatory AUC value of >0.800. A representative 2-dimensional view of all the MS peaks, with the m/z displayed along the X-axis and the LC retention time (RT) along the Y-axis, is shown in Figure 1A. The 103 MS peaks which distinguished between colorectal cancer patients and healthy controls with AUC values of >0.800 are highlighted in red.

Eleven tandem mass spectrometry spectra acquired from those 103 peaks matched 6 proteins in the database with Mascot score >40 (Supplementary Table S1). We focused attention on a MS peak (ID 83) derived from the amino acid sequence of ADFP gene product (Supplementary Fig. S1) because the expression level of adipophilin was previously reported to be upregulated in clear cell renal carcinoma, but no such upregulation has been described in colorectal cancer. The adipophilin-derived MS peak (ID 83, at 749 m/z and 47.4 minutes) in representative patients from cancer and control groups is shown in Figure 1B. The distribution of the MS peak (ID 83) in patients with colorectal cancer (red) and healthy controls (blue) in the training cohort (AUC = 0.814) is shown in Figure 1C. The differential expression and identification of adipophilin was confirmed by denaturing SDS-PAGE and immunoblotting analyses (Fig. 1D).

**Protein microarray validation**

To further validate the utility of using adipophilin for the diagnosis of colorectal cancer, the relative level of adipophilin in a total of 323 plasma samples was quantified using reverse-phase protein microarrays (Fig. 2). Quadruplicate spots for representative cases with high and low levels of adipophilin are shown in Figure 2. The power of plasma adipophilin level to discriminate colorectal cancer was validated in 2 larger independent validation cohorts (V1: \( n = 210 \), V2: \( n = 113 \)) that included early-stage colorectal cancer (Table 1). In the V1 cohort, the adipophilin level was significantly higher in patients
with colorectal cancer than in healthy controls (Welch’s t test \( P = 5.49 \times 10^{-10} \), Fig. 3A and Table 1), with an AUC value of 0.767 (95% CI: 0.699–0.825; Fig. 3B). The colorectal cancer discriminatory power of adipophilin was also apparent in the V2 cohort (\( P = 0.00009 \), Fig. 3C and Table 1), with an AUC value of 0.742 (95% CI: 0.625–0.836; Fig. 3B).

There was no difference in the plasma level of adipophilin among different disease stages (Kruskal–Wallis test \( P = 0.280 \)). Notably, however, the adipophilin level was significantly higher even in patients with stage I or II disease (localized early colorectal cancer without metastasis to lymph nodes) than in healthy controls, whereas the CEA level in early-stage patients did not significantly differ from that of healthy controls (Table 2).

**Adipophilin complements CEA**

The levels of adipophilin and CEA were not mutually correlated (Pearson’s \( r = 0.13 \) in the V1 cohort and 0.12 in the V2 cohort), and the AUC values of CEA in both cohorts (Fig. 3D) were comparable with that of a previous report (26). Combining adipophilin and CEA quantitation yielded a significant improvement in the ability to distinguish patients with colorectal cancer from healthy controls compared with quantitating CEA alone; the AUC improved to 0.849 (95% CI: 0.790–0.896) in the V1 cohort (\( P = 0.0008 \)) and 0.787 (0.673–0.874) in the V2 cohort (\( P = 0.022 \); Fig. 3D), indicating that plasma adipophilin and CEA have complementary diagnostic utility.

Due to the low prevalence of colorectal cancer among an asymptomatic population, a high specificity is required for a screening biomarker. If we defined the upper limit of the normal range of the composite index (adipophilin plus CEA; Fig. 3D) to include 95% of healthy controls in each validation cohort, the sensitivity of the index was 54% (95% CI: 41–66) in the V1 cohort and 31% (13–56) in the V2 cohort.

**Adipophilin expression in colorectal cancer**

The expression and cellular distribution of adipophilin in colorectal cancer tissues were examined using an immunohistochemical assay of 8 well differentiated, 10...
moderately differentiated, and 2 poorly differentiated adenocarcinomas. A total of 14 of 20 cancer tissues from the well- and moderately differentiated cases showed positive staining for adipophilin, but neither of the 2 poorly differentiated samples was positive. In a majority of the well- and moderately differentiated tumors, strong staining for adipophilin was observed in the cytoplasm or cell membrane of tumor glands facing the basement membrane (Fig. 4A and B). Adipophilin was not expressed in normal epithelial cells of the colorectal mucosa (Fig. 4C). The expression of adipophilin was clearly diminished in cancer cells invading in a scattered manner (Fig. 4D), which is consistent with the lack of staining observed in poorly differentiated tumor samples.

Discussion

In this study, we first enriched the LMW plasma protein fraction using HFMT, then compared its contents between patients with colorectal cancer and healthy controls using 2DICAL (Fig. 1). The high efficacy of combining HFMT and 2DICAL for plasma biomarker discovery was shown for the first time in our previous study of pancreatic cancer (17), and the present results further strengthened the credible evidence for the applicability of this combination of methods to all types of future plasma biomarker research. Any biomarker candidate identified by proteomic approaches must be validated using a different...
method in a statistically sufficient number of cases and controls before it can be considered for clinical application. We employed another innovative technology, a reverse-phase protein microarray, for independent validation of our finding that adipophilin discriminates colorectal cancer (Fig. 2). Our high-density protein microarray enabled the high-throughput quantification of 1 protein in hundreds of clinical samples in 1 experiment (18), while keeping the required volume of each sample to a minimum (nanoliter level). Although the availability of clinical samples is often limited, it is often necessary to waste hundreds of microliters of samples for preliminary experiments involving techniques such as conventional ELISA. Because of their minimal sample requirements, plasma microarrays are considered to be ideal alternatives to ELISAs for biomarker validation. However, the absolute concentration and optimal cut-off value of adipophilin were not determined in this study. It may be necessary to establish an ELISA prior to the clinical application of the present results.

Although the expression of adipophilin is known to be induced in various types of pathologic and physiologic conditions, such as lactating mammary epithelial cells, few studies have assessed the significance of its expression in cancer cells (27, 28). We found that adipophilin is expressed in well- or moderately differentiated adenocarcinomas, but not in the adjacent normal colonic mucosa or poorly differentiated adenocarcinoma (Fig. 4). The immunohistochemical data suggest that the expression of adipophilin is induced during the process of early colorectal carcinogenesis but lost during the process of cancer promotion. Consistent with our findings, Yao and colleagues also reported that adipophilin expression correlates well with the differentiation status of clear cell renal carcinoma of the kidney (29). They also reported that adipophilin expression is a prognostic factor for the cancer-specific survival of patients with renal clear cell carcinoma (29). The prognostic significance of adipophilin expression in colorectal cancer, however, remains to be determined.

The expression of adipophilin is known to be induced by hypoxia inducible factor (HIF) and the peroxisome proliferator-activated receptor (PPAR) family of proteins. Both HIF and PPAR were reported to be closely involved in carcinogenesis, especially in colorectal cancer (30, 31). Moreover, PPAR may be a molecular target of anticancer therapy (32). Because the exact nature of the interactions between these proteins (adipophilin, HIF, and PPAR) has not been extensively investigated, further studies are needed to elucidate the biological and clinicopathologic significance of adipophilin expression in colorectal

### Table 2. Plasma adipophilin and CEA levels according to clinical stage of colorectal cancer [UICC TNM classification of malignant tumors, 6th edition (2002)] in the V1 cohort

<table>
<thead>
<tr>
<th></th>
<th>Colorectal cancer patients</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stage I</td>
<td>Stage II</td>
</tr>
<tr>
<td>Adipophilin&lt;sup&gt;a&lt;/sup&gt;, mean (SD)</td>
<td>3.90 (0.05)</td>
<td>3.91 (0.07)</td>
</tr>
<tr>
<td>P&lt;sup&gt;b&lt;/sup&gt; (vs. healthy controls)</td>
<td>1.07 × 10&lt;sup&gt;-5&lt;/sup&gt;</td>
<td>3.31 × 10&lt;sup&gt;-6&lt;/sup&gt;</td>
</tr>
<tr>
<td>CEA, mean (SD), ng/mL</td>
<td>2.63 (1.71)</td>
<td>13.7 (36.2)</td>
</tr>
<tr>
<td>P&lt;sup&gt;b&lt;/sup&gt; (vs. healthy controls)</td>
<td>0.20</td>
<td>0.09</td>
</tr>
</tbody>
</table>

<sup>a</sup> Measured using a reverse-phase protein microarray (values were transformed into logarithmic variables).

<sup>b</sup> Welch’s t test (comparison with healthy controls).

---

Figure 4. Immunohistochemical analysis of adipophilin in colorectal cancer (A–D) and adjacent normal colonic mucosa (designated by N; C). Original magnification: A and D = 100 ×; B = 400 ×; C = 40 ×.
cancer. The present findings may provide novel insights into the molecular mechanism of colorectal cancer development and progression and into the development of new anticancer therapeutics.

There are some limitations to our study. First, we have no data about the body mass index of cases included in this study. The relationship between obesity and an increased risk of colon cancer is now generally accepted (35–37), and alteration of adipokine levels can reportedly affect intestinal carcinogenesis (36). Although adipophilin was originally identified as a marker of adipocyte development (27, 37), its relevance to body shape and cachexia remain to be elucidated. Adipophilin is a 50 kDa protein belonging to the PAT family (perilipin, adipophilin, TIP47, S3–12, and OXPAT), which comprises proteins involved in the coating of lipid droplets (27, 38, 39). Second, we have no data of FOB test results for the cases used in this study and thus it was not possible to show the superiority of adipophilin to FOB. However, a recent large-scale study showed that 11% of patients with negative FOB results had cancers or adenomas that required treatment (40). Because the adipophilin level was significantly elevated, even in patients with localized early colorectal cancer (Table 2), adipophilin may supplement or surpass the diagnostic power of FOB. Finally, there was a difference in the age distribution between cancer and control in all cohorts. However, age did not correlate with plasma adipophilin level in the cancer and control group (Pearson’s r = 0.03 and r = 0.09, respectively). We therefore estimate the influence of difference in age to be negligible.

In conclusion, we identified plasma adipophilin as a new tumor marker for colorectal cancer using LMW protein profiling. The increase of plasma adipophilin level in colorectal cancer was validated in 2 larger cohorts, and the diagnostic power was revealed to be superior to that of CEA in the detection of early-stage (stages I and II) colorectal cancer. To our knowledge, this is the first study showing the expression of adipophilin in colorectal cancer. While bearing the above limitations in mind, an independent validation study is warranted.

Disclosure of Potential Conflicts of Interest

The sponsors of the study had no role in the design of the study, data collection, data analysis and interpretation, the decision to submit the manuscript for publication, or the writing of the manuscript.

Acknowledgments

We thank Ms. Ayako Igarashi, Ms. Tomoko Umaki, and Ms. Yuka Nakamura for their technical assistance.

Grant Support

This study was supported by the “Program for Promotion of Fundamental Studies in Health Sciences” conducted by the National Institute of Biomedical Innovation of Japan, the “Third-Term Comprehensive Control Research for Cancer” and “Research on Biological Markers for New Drug Development” conducted by the Ministry of Health and Labor of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 27, 2011; revised July 12, 2011; accepted August 1, 2011; published OnlineFirst August 9, 2011.
Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Junichi Matsubara, Kazufumi Honda, Masaya Ono, et al.

Cancer Epidemiol Biomarkers Prev  Published OnlineFirst August 9, 2011.

Updated version  Access the most recent version of this article at: 
doi:10.1158/1055-9965.EPI-11-0400

Supplementary Material  Access the most recent supplemental material at: 
http://cebp.aacrjournals.org/content/suppl/2011/08/09/1055-9965.EPI-11-0400.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.